Chronic myelomonocytic leukemia or myelodysplastic/myeloproliferative neoplasm (unacceptable MDS subtypes); uncontrolled bacterial, viral or fungal infection (currently taking medication and with progression or no clinical improvement) at time of enrollment.Xx_NEWLINE_xXREGISTRATION STEP 2-RANDOMIZATION: Patients must not have active infection (systemic bacterial, fungal, or viral infection) that is not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement despite appropriate antibiotics or other treatment)Xx_NEWLINE_xXAcute bacterial or fungal infection requiring intravenous antibiotics at the time of registration.Xx_NEWLINE_xXPatients must not have systemic fungal, bacterial, viral or other infection that is not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)Xx_NEWLINE_xXActive and clinically significant bacterial, fungal, or viral infectionXx_NEWLINE_xXActive symptomatic fungal, bacterial and/or viral infection including active HIV or viral (A, B or C) hepatitis.Xx_NEWLINE_xXPatients must not have a systemic bacterial, fungal, or viral infection that is not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement despite appropriate antibiotics or other treatment)Xx_NEWLINE_xXPatients with active bacterial or fungal infections unresponsive to medical therapyXx_NEWLINE_xXKnown active bacterial, viral, fungal, mycobacterial, or other infectionXx_NEWLINE_xXOngoing treatment for systemic bacterial, fungal, or viral infection at ScreeningXx_NEWLINE_xXPresence of fungal, bacterial, viral, or other infection requiring oral or IV antimicrobials for management within 7 days of first dose AMG 757Xx_NEWLINE_xXActive and clinically significant bacterial, fungal, or viral infectionXx_NEWLINE_xXKnown active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics within 4 weeks prior to first infusionXx_NEWLINE_xXActive and clinically significant bacterial, fungal, or viral infectionXx_NEWLINE_xXEvidence of active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days prior to the initiation of study drug.Xx_NEWLINE_xXActive bacterial or systemic viral or fungal infectionsXx_NEWLINE_xXActive, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapyXx_NEWLINE_xXKnown active infections (bacterial, fungal, viral including HIV positivity).Xx_NEWLINE_xXActive, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy. Known infection with human immunodeficiency virus, or an active infection with hepatitis B or hepatitis C.Xx_NEWLINE_xXEvidence of other clinically significant uncontrolled condition(s) including, but not limited to, uncontrolled systemic infection (viral, bacterial, or fungal)Xx_NEWLINE_xXCOHORT 1: Has an active uncontrolled infection requiring systemic therapy (viral, bacterial or fungal); patients with infection under active treatment and controlled with antibiotics are eligibleXx_NEWLINE_xXCOHORT 2: Has an active uncontrolled infection requiring systemic therapy (viral, bacterial or fungal); patients with infection under active treatment and controlled with antibiotics are eligibleXx_NEWLINE_xXSymptomatic/active bacterial, or fungal, or any other opportunistic infectionXx_NEWLINE_xXActive, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy. Known infection with human immunodeficiency virus (HIV), or an active infection with hepatitis B or hepatitis C.Xx_NEWLINE_xXUncontrolled bacterial, viral or fungal infection in the 6 weeks before enrollment.Xx_NEWLINE_xXKnown uncontrolled fungal, bacterial, and/or viral infection ?Grade 2.Xx_NEWLINE_xXActive bacterial, fungal or viral infectionXx_NEWLINE_xXMust not have an active symptomatic fungal, bacterial or viral infection, including human immunodeficiency virus (HIV) or Hepatitis A, B, or CXx_NEWLINE_xXActive, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapyXx_NEWLINE_xXActive, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy. Known infection with HIV, or an active infection with hepatitis B or hepatitis C.Xx_NEWLINE_xXActive bacterial, viral, or fungal infection requiring systemic therapy.Xx_NEWLINE_xXUncontrolled viral, bacterial, or fungal infections (human immunodeficiency virus [HIV] infection permitted if viral load undetectable)Xx_NEWLINE_xXActive bacterial, fungal, or viral infection requiring systemic treatment; patients who are receiving treatment for infections that are under control may be included in this studyXx_NEWLINE_xXUncontrolled systemic fungal, bacterial, viral, or other serious infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment); may be enrolled if controlled on treatmentXx_NEWLINE_xXSystemic fungal, bacterial, viral or other infection that is not controlled.Xx_NEWLINE_xXPatients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)Xx_NEWLINE_xXCurrent active, uncontrolled bacterial, viral, or fungal infectionXx_NEWLINE_xXActive bacterial or viral infectionXx_NEWLINE_xXActive, uncontrolled bacterial, viral, or fungal infections, within 7 days of study entry requiring systemic therapy.Xx_NEWLINE_xXEvidence of an ongoing systemic bacterial, fungal, or viral infection.Xx_NEWLINE_xXActive, uncontrolled bacterial, viral, or fungal infections, within 7 days of study entry requiring systemic therapy.Xx_NEWLINE_xXActive and clinically significant bacterial, fungal or viral infection\r\n* Known infections with hepatitis B (HBV) or hepatitis C (HCV)\r\n* Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness not controlled (with undetectable viral load) on highly active antiretroviral therapy (HAART) therapy; patients on HAART with undetectable viral loads may be eligible per principal investigator (PI) judgmentXx_NEWLINE_xXUncontrolled bacterial, fungal, or viral infections including HIV - chronic asymptomatic viral hepatitis is allowedXx_NEWLINE_xXParticipants with active viral, bacterial or fungal infection requiring concurrent antiviral or antibioticsXx_NEWLINE_xXActive >= grade 3 viral, bacterial, or fungal infection within 2 weeks prior to day 1 of protocol therapyXx_NEWLINE_xXEvidence of active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days prior to the initiation of study drug. Patients requiring any systemic antiviral, antifungal, or antibacterial therapy for active infection must have completed treatment no less than one week prior to the initiation of study drugXx_NEWLINE_xXPresence of a systemic fungal, bacterial, viral or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment).Xx_NEWLINE_xXActive bacterial, fungal, or viral infectionXx_NEWLINE_xXAny clinically significant infection defined as any acute viral, bacterial, or fungal infection that requires specific treatment. NOTE: Anti-infective treatment must be completed ? 7 days prior to study registration.Xx_NEWLINE_xXCurrent uncontrolled bacterial, viral or fungal infection (currently taking medication with evidence of progression of clinical symptoms or radiologic findings).Xx_NEWLINE_xXPatients with uncontrolled bacterial, viral or fungal infections (currently taking medication and with progression or no clinical improvement) at time of enrollment.Xx_NEWLINE_xXPatients with active, uncontrolled bacterial, viral or fungal infection(s) requiring systemic therapyXx_NEWLINE_xXParticipant has an uncontrolled infection. If a bacterial or viral infection is present, the participant must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to registration. If a fungal infection is present, the participant must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to registration.Xx_NEWLINE_xXParticipant has an uncontrolled infection. If a bacterial or viral infection is present, the participant must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to randomization. If a fungal infection is present, the participant must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to randomization.Xx_NEWLINE_xXOngoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infections)Xx_NEWLINE_xXUncontrolled bacterial, viral, or fungal infection at the time of enrollment. Uncontrolled is defined as currently taking medication and with progression or no clinical improvement on adequate medical treatment.Xx_NEWLINE_xXPROCUREMENT EXCLUSION: Active bacterial fungal or viral infectionXx_NEWLINE_xXTREATMENT EXCLUSION: Active bacterial, viral or fungal infectionXx_NEWLINE_xXActive bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV)Xx_NEWLINE_xXActive and uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy. Known infection with human immunodeficiency virus (HIV), or an active infection with hepatitis B or hepatitis C.Xx_NEWLINE_xXSystemic fungal, bacterial, viral or other infection that is not controlledXx_NEWLINE_xXParticipants receiving antibiotic therapy for treatment of a bacterial infection or bacterial prophylaxis upon admission for allogeneic HSCT; use of any agent (e.g. sulfamethoxazole/trimethoprim) for prophylaxis of pneumocystis jirovecii pneumonia is permitted; concurrent use of anti-fungal and anti-viral therapies is also permittedXx_NEWLINE_xXHIV or active bacterial, viral or fungal infectionsXx_NEWLINE_xXCurrent uncontrolled bacterial, viral or fungal infection (currently taking medication with evidence of progression of clinical symptoms or radiologic findings); the principal investigator is the final arbiter of this criterionXx_NEWLINE_xXActive, uncontrolled bacterial, viral, fungal, or other opportunistic infection requiring systemic therapy.Xx_NEWLINE_xXActive invasive fungal infection requiring treatment with anti-fungal medicationXx_NEWLINE_xXPatients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)Xx_NEWLINE_xXActive uncontrolled acute fungal, bacterial, or other infection that is unresponsive to therapy at time of study drug dosingXx_NEWLINE_xXSubjects with active or uncontrolled bacterial, viral, or fungal infections requiring systemic therapyXx_NEWLINE_xXExhibits evidence of other clinically significant uncontrolled condition(s), including, but not limited to: uncontrolled systemic infection (viral, bacterial, or fungal), diagnosis of fever and neutropenia within 1 week prior to first dose of study drug.Xx_NEWLINE_xXActive systemic viral, bacterial or fungal infection requiring treatmentXx_NEWLINE_xXHave an active fungal, bacterial, and/or known viral infectionXx_NEWLINE_xXUncontrolled viral or bacterial infection at the time of study enrollmentXx_NEWLINE_xXAUTOLOGOUS APHERESIS: Severe intercurrent bacterial, viral or fungal infectionXx_NEWLINE_xXTREATMENT WITH SJCAR19: Severe, uncontrolled bacterial, viral or fungal infectionXx_NEWLINE_xXEvidence of an ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infections) at the time of start of voruciclib therapyXx_NEWLINE_xXSubjects with uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate antibiotics or other treatment at the time of leukapheresis or during day 0 (within 24 hrs of CAR T infusion)Xx_NEWLINE_xXHaving any uncontrolled illness including ongoing or active bacterial, viral or fungal infectionXx_NEWLINE_xXKnown active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to cycle 1, day 1Xx_NEWLINE_xXSubject exhibits evidence of uncontrolled systemic infection requiring therapy (viral, bacterial or fungal)Xx_NEWLINE_xXEvidence of an ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infections) at the time of start of study therapy. Note: Subjects with localized fungal infections of skin or nails are not precluded from participation.Xx_NEWLINE_xXAny known clinically significant active infection including bacterial, fungal or viral including hepatitis B (HBV), hepatitis C (HCV) or any underlying disease or in the recent past which could compromise enrollment and safety of the patient.Xx_NEWLINE_xXKnown active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior study therapyXx_NEWLINE_xXEvidence of active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days prior to the initiation of study drug. Patients requiring any systemic antiviral, antifungal, or antibacterial therapy for active infection must have completed treatment no less than one week prior to the initiation of study drug.Xx_NEWLINE_xXPresence of fungal, bacterial, viral, or other infection requiring IV antimicrobials for management within 7 days of enrollment. Note: Simple UTI and uncomplicated bacterial pharyngitis are permitted if responding to active treatment and after consultation with sponsor.Xx_NEWLINE_xXAny active grade 3 or higher (per NCI CTCAE version 4.03) viral, bacterial, or fungal infection within 2 weeks of the first dose of the study drug. Routine antimicrobial prophylaxis is permitted.Xx_NEWLINE_xXThe participant has an active fungal, bacterial, and/or known viral infection including human immunodeficiency virus (HIV) or viral (A, B, or C) hepatitis (screening is not required).Xx_NEWLINE_xXCurrently receiving systemic antimicrobial treatment for active infection (viral, bacterial, or fungal) at the time of first dose of enfortumab vedotin. Routine antimicrobial prophylaxis is permitted.Xx_NEWLINE_xXActive, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapyXx_NEWLINE_xXPresence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management.Xx_NEWLINE_xXParticipant exhibits evidence of other clinically significant uncontrolled systemic infection requiring therapy (viral, bacterial or fungal).Xx_NEWLINE_xXActive bacterial, fungal or viral infection.Xx_NEWLINE_xXThe participant has an active fungal, bacterial, and/or known severe viral infection including human immunodeficiency virus (HIV) or viral (A, B, or C) hepatitis (screening is not required).Xx_NEWLINE_xXActive bacterial or fungal infections requiring systemic treatment within 7 days of treatmentXx_NEWLINE_xXSubjects with uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate antibiotics or other treatment at the time of leukapheresisXx_NEWLINE_xXInfection Criteria\r\n* Positive blood culture within 48 hours of study enrollment\r\n* Fever above 38.2 within 48 hours of study enrollment with clinical signs of infection; fever that is determined to be due to tumor burden is allowed if patients have documented negative blood cultures for at least 48 hours prior to enrollment and no concurrent signs or symptoms of active infection or hemodynamic instability\r\n* Active fungal, viral, bacterial, or protozoal infection requiring IV treatment; chronic prophylaxis therapy to prevent infections is allowedXx_NEWLINE_xXUncontrolled bacterial infectionXx_NEWLINE_xXUncontrolled bacterial, viral or fungal infection in the 6 week before enrollmentXx_NEWLINE_xXKnown uncontrolled fungal, bacterial, and/or viral infection ?Grade 2Xx_NEWLINE_xXHave an active fungal, bacterial and/or known viral infection including human immunodeficiency virus or viral (A, B, or C) hepatitis (screening is not required).Xx_NEWLINE_xXUncontrolled active infection (bacterial, fungal, viral, mycobacterial) not responding to treatment with intravenous antibiotics, antiviral or antifungal agentsXx_NEWLINE_xXAbsence of uncontrolled active infection (bacterial, fungal, viral, mycobacterial) not responding to treatment with antibiotics, antiviral agents, or antifungal agentsXx_NEWLINE_xXActive viral, bacterial, or fungal infection progressing on current treatmentXx_NEWLINE_xXActive bacterial or fungal infections unresponsive to medical therapyXx_NEWLINE_xXUncontrolled bacterial, fungal or viral infections with progression of clinical symptoms despite therapyXx_NEWLINE_xXUncontrolled and active systemic fungal, bacterial, viral, or other infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment).Xx_NEWLINE_xXActive bacterial, fungal or viral infection not controlled by adequate treatment, at enrollment.Xx_NEWLINE_xXhave any clinically significant infection, defined as any acute viral, bacterial, or fungal infection that requires systemic treatment or have received any anti-infective treatment within 7 days prior to the screening visit;Xx_NEWLINE_xXKnown active bacterial, viral, fungal, mycobacterial, or other infection (excluding fungal infections of nail beds) or any major episode of infection requiring treatment with IV antibiotics or hospitalization (related to the completion of the course of antibiotics) within 4 weeks before the start of cycle 1Xx_NEWLINE_xXActive bacterial, fungal or viral infection not controlled by adequate treatment, at enrollmentXx_NEWLINE_xXActive bacterial or viral infections requiring systemic therapyXx_NEWLINE_xXCurrent uncontrolled bacterial, fungal or viral infections (defined as currently taking medication and having continuing clinical symptoms or radiologic findings)Xx_NEWLINE_xXUncontrolled active infections (viral, bacterial, and fungal)Xx_NEWLINE_xXActive, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapyXx_NEWLINE_xXKnown active bacterial, viral, fungal, mycobacterial, or other infection (excluding fungal infections of nail beds) or any major episode of infection requiring treatment with IV antibiotics or hospitalization (related to the completion of the course of antibiotics) within 4 weeks before the start of cycle 1Xx_NEWLINE_xXPatients with uncontrolled systemic fungal, bacterial, viral or other infection are ineligibleXx_NEWLINE_xXUncontrolled bacterial, fungal or viral infections including human immunodeficiency virus (HIV)-1/2 or active hepatitis C/B - chronic asymptomatic viral hepatitis is allowedXx_NEWLINE_xXParticipant exhibits evidence of other clinically significant uncontrolled systemic infection requiring therapy (viral, bacterial or fungal).Xx_NEWLINE_xXPresence of fungal, bacterial, viral, or other infection requiring IV antimicrobials for management. Note: Simple urinary tract infection (UTI) and uncomplicated bacterial pharyngitis are permitted if responding to active treatment.Xx_NEWLINE_xXUncontrolled bacterial, fungal or viral infections including human immunodeficiency virus (HIV)-1/2 or active hepatitis C/B - chronic asymptomatic viral hepatitis is allowedXx_NEWLINE_xXPresence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring intravenous antimicrobials for management.Xx_NEWLINE_xXKnown active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment or significant infections within 2 weeks before the start of Cycle 1Xx_NEWLINE_xXParticipants with a history of an opportunistic fungal infection or active fungal infection requiring, or at high risk of requiring, prophylactic or treatment with fluconazole, voriconazole or posaconazoleXx_NEWLINE_xXUncontrolled systemic fungal, bacterial, viral, or other infectionXx_NEWLINE_xXUncontrolled active systemic fungal, bacterial, viral, or other infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment), or intravenous anti infective treatment within 2 weeks before first dose of study drug.Xx_NEWLINE_xXUncontrolled systemic fungal, bacterial or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy and/or other treatment)Xx_NEWLINE_xXActive systemic fungal, bacterial, viral, or other infection, unless disease is under treatment with anti-microbials and/or controlled or stable; patients with fever thought to be likely secondary to leukemia are eligible; known hypersensitivity to any study drugXx_NEWLINE_xXActive bacterial, viral, or fungal infections, requiring systemic therapy apart from anti-viral maintenance therapy for HIV.Xx_NEWLINE_xXDocumented fungal infection within 3 months of BMTXx_NEWLINE_xXKnown active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior study therapyXx_NEWLINE_xXActive, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapyXx_NEWLINE_xXAcute bacterial or fungal infection requiring intravenous antibiotics within 7 days of enrollment;Xx_NEWLINE_xXEvidence of active infection that requires anti-bacterial, anti-viral, or anti-fungal therapy =< 7 days prior to initiation of study drug therapyXx_NEWLINE_xXAcute bacterial or fungal infection requiring intravenous antibiotics at the time of registrationXx_NEWLINE_xXHave an active fungal, bacterial, and/or known viral infection including human immunodeficiency virus (HIV) or viral (A, B, or C) hepatitisXx_NEWLINE_xXActive, uncontrolled bacterial, viral or fungal infection, requiring systemic therapyXx_NEWLINE_xXEvidence of an ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infections) at the time of start of study therapy. Note: Subjects with localized fungal infections of skin or nails are eligible.Xx_NEWLINE_xXActive systemic fungal, bacterial, viral, or other infection, unless disease is under treatment with anti-microbials and/or controlled or stable (e.g. if specific, effective therapy is not available/feasible or desired [e.g. chronic viral hepatitis, human immunodeficiency virus (HIV)]); patient needs to be clinically stable as defined as being afebrile and hemodynamically stable for 24-48 hoursXx_NEWLINE_xXActive bacterial, fungal or viral infectionXx_NEWLINE_xXPatients with uncontrolled active infection (viral, bacterial, and fungal) are not eligibleXx_NEWLINE_xXUncontrolled bacterial, viral, or fungal infection at the time of enrollment; uncontrolled is defined as currently taking medication and with progression or no clinical improvement on adequate medical treatmentXx_NEWLINE_xXActive >= grade 3 (per NCI CTCAE v4) viral, bacterial, or fungal infection within 2 weeks prior to initiation of study treatmentXx_NEWLINE_xXDoes not have current uncontrolled bacterial, fungal, or viral infectionXx_NEWLINE_xXPatients with uncontrolled bacterial, viral or fungal infectionsXx_NEWLINE_xXUncontrolled active systemic infection (viral, bacterial, and fungal)Xx_NEWLINE_xXActive bacterial, fungal or viral infections unresponsive to medical therapyXx_NEWLINE_xXAcute bacterial, viral, or fungal infection requiring treatment at the time of registrationXx_NEWLINE_xXActive systemic fungal, bacterial, viral, or other infection, unless disease is under treatment with anti-microbials and/or controlled or stable (e.g. if specific, effective therapy is not available/feasible or desired [e.g. chronic viral hepatitis, human immunodeficiency virus (HIV)]); patient needs to be clinically stable as defined as being afebrile and hemodynamically stable for 24-48 hours prior to study day 0, unless fever is thought to be secondary to the underlying hematologic diseaseXx_NEWLINE_xXUncontrolled active infection (bacterial, viral, fungal, mycobacterial) not responding to treatment with intravenous antibiotics, antiviral or antifungal agents, or long-term treatment with oral agentsXx_NEWLINE_xXEXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Uncontrolled active infection (bacterial, viral, fungal, mycobacterial) not responding to treatment with intravenous antibiotics, antiviral or antifungal agents, or long-term treatment with oral agentsXx_NEWLINE_xXEXCLUSION CRITERIA FOR TNBC: Uncontrolled active infection (bacterial, viral, fungal, mycobacterial) not responding to treatment with intravenous antibiotics, antiviral or antifungal agents, or long-term treatment with oral agentsXx_NEWLINE_xXActive uncontrolled systemic fungal, bacterial or viral infectionXx_NEWLINE_xXPatient has active and uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapyXx_NEWLINE_xXActive, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapyXx_NEWLINE_xXuncontrolled infection including evidence of ongoing systemic bacterial, fungal, or viral infection (excluding viral upper respiratory tract infections) at the time of initiation of study treatment;Xx_NEWLINE_xXUncontrolled active systemic infection (viral, bacterial, and fungal)Xx_NEWLINE_xXActive bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV) , requiring treatment with intravenous (IV) antibiotic, IV anti-fungal, or anti-viral; (testing is not required for eligibility)Xx_NEWLINE_xXUncontrolled viral, fungal, or bacterial infectionXx_NEWLINE_xXCERITINIB EXCLUSION CRITERIA: Known active infection (bacterial, fungal, viral including human immunodeficiency virus [HIV] positivity)Xx_NEWLINE_xXREGORAFENIB EXCLUSION CRITERIA: Known active infection (bacterial, fungal, viral); viral infection includes known HIV positivity, or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapyXx_NEWLINE_xXENTRECTINIB EXCLUSION CRITERIA: Known active infection (bacterial, fungal, viral including HIV positivity)Xx_NEWLINE_xXActive systemic fungal, bacterial, viral or other infection, unless disease is under treatment with antimicrobials and considered controlled in the opinion of the investigatorXx_NEWLINE_xXPatient with uncontrolled systemic fungal, bacterial, viral or other infection with ongoing signs/symptoms despite appropriate treatmentXx_NEWLINE_xXActive uncontrolled bacterial, viral or fungal infectionsXx_NEWLINE_xXHave active and clinically relevant bacterial, fungal, or viral infection, including known Hepatitis A, B, or C or human immunodeficiency virus (HIV) (testing not required)Xx_NEWLINE_xXActive serious systemic disease, including active bacterial or fungal infectionXx_NEWLINE_xXPatients with systemic fungal, bacterial, viral or other infection that is exhibiting ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics or other treatmentXx_NEWLINE_xXActive viral, fungal, bacterial or other infectionXx_NEWLINE_xXActive fungal infection or bacterial sepsisXx_NEWLINE_xXPatients should not have any uncontrolled illness including ongoing or active bacterial, viral or fungal infectionXx_NEWLINE_xXUncontrolled active infections (viral, bacterial, and fungal); the study chair will be the final arbiter of this criterionXx_NEWLINE_xXUncontrolled bacterial, viral or fungal infection defined as currently taking medication and progression of clinical symptomsXx_NEWLINE_xXPatients must not have an uncontrolled bacterial, fungal or viral infection, defined as progressive symptoms despite therapy, at the time of the CD8+ memory T-cell infusion; asymptomatic viremia is allowedXx_NEWLINE_xXPatients with uncontrolled active infection (viral, bacterial, and fungal) are not eligibleXx_NEWLINE_xXPatients with documented active bacterial, viral or fungal infection, untreated systematic peptic ulcer disease, uncontrolled diabetes mellitus or serious concurrent medical disease that could limit survival to less than 3 monthsXx_NEWLINE_xXPatients with uncontrolled active infections (viral, bacterial, or fungal) are not eligibleXx_NEWLINE_xXPART 1: Uncontrolled viral, bacterial, or fungal infections at the time of study enrollmentXx_NEWLINE_xXPART 2: Uncontrolled viral or bacterial infection at the time of study enrollmentXx_NEWLINE_xXHave an active systemic bacterial or fungal infection requiring antimicrobial therapy (prophylactic antimicrobial therapy administered as standard of care is allowed)Xx_NEWLINE_xXCurrent uncontrolled bacterial, viral or fungal infection (currently taking medication with evidence of progression of clinical symptoms or radiologic findings)Xx_NEWLINE_xXAcute bacterial or fungal infection requiring intravenous antibiotics at the time of registrationXx_NEWLINE_xXPatients with other conditions not related to CMV infection (e.g. uncontrolled bacterial sepsis or invasive fungal infection) which are also life-threatening and which would preclude evaluation of the effects of a T-cell infusion.Xx_NEWLINE_xXPatients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)Xx_NEWLINE_xXActive bacterial, viral, or fungal infection requiring systemic therapy or operative or radiological intervention.Xx_NEWLINE_xXPatients with active uncontrolled bacterial, viral or fungal infections (undergoing appropriate treatment and with progression of clinical symptoms)Xx_NEWLINE_xXOngoing bacterial, viral, or antifungal infection requiring antimicrobial treatment with the exception of thrushXx_NEWLINE_xXPatients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)Xx_NEWLINE_xXEvidence of uncontrolled bacterial, viral, or fungal infections (currently taking medication and progression of clinical symptoms) within one month prior to starting the conditioning regimenXx_NEWLINE_xXKnown active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics, except if for tumor fever) within 4 weeks prior to the start of cycle 1; patients with suspected active or latent tuberculosis (latent tuberculosis needs to be confirmed by positive interferon-gamma release assay)Xx_NEWLINE_xXAn uncontrolled bacterial, viral, or fungal infection or an active duodenal ulcer, until these conditions are corrected or controlled.Xx_NEWLINE_xXUncontrolled bacterial or viral infections, or known HIV, hepatitis B or C infectionXx_NEWLINE_xXSystemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)Xx_NEWLINE_xXDoes not have current uncontrolled bacterial, fungal, or viral infectionXx_NEWLINE_xXUncontrolled viral, bacterial, or fungal infectionsXx_NEWLINE_xXKnown mixed invasive mold fungal infection including Zygomycetes, and/or a known invasive Aspergillus fungal infection in which either study drug may not be considered active.Xx_NEWLINE_xXActive uncontrolled bacterial, viral, or fungal infection until these conditions are corrected or controlledXx_NEWLINE_xXPatients with active viral, bacterial or systemic fungal infection requiring treatment.Xx_NEWLINE_xXActive uncontrolled bacterial, viral or fungal infectionsXx_NEWLINE_xXActive, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapyXx_NEWLINE_xXActive bacterial, viral or fungal infectionsXx_NEWLINE_xXUncontrolled bacterial, viral or fungal infections.Xx_NEWLINE_xXUncontrolled viral, bacterial or fungal infectionXx_NEWLINE_xXPatients with active uncontrolled life threatening infection (s) from viral, bacterial, fungal or other organisms will be excluded; patients with human immunodeficiency virus (HIV) infection will be excludedXx_NEWLINE_xXUncontrolled bacterial, mycobacterial, or fungal infectionXx_NEWLINE_xXActive, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy. Known infection with HIV, or an active infection with hepatitis B or hepatitis CXx_NEWLINE_xXAfebrile with clear chest imaging and no signs of active viral, bacterial, fungal infection unless determined to be, at the discretion of the investigator, not clinically significant in the context of this studyXx_NEWLINE_xXPresence of a fungal infection requiring systemic antifungal treatment at enrollmentXx_NEWLINE_xXActive ongoing viral, bacterial, or fungal infectionXx_NEWLINE_xXActive viral, bacterial or fungal infection unless adequately treated; for fungal infection, patient should have completed full course of antifungal therapy with resolution of infectionXx_NEWLINE_xXActive viral, bacterial or fungal infectionXx_NEWLINE_xXCurrent uncontrolled bacterial, viral or fungal infection (currently taking medication with evidence of progression of clinical symptoms or radiologic findings)Xx_NEWLINE_xXUncontrolled viral or bacterial infection at the time of study enrollmentXx_NEWLINE_xXUncontrolled viral or bacterial infection at the time of study enrollmentXx_NEWLINE_xXActive bacterial infection within one week of HCTXx_NEWLINE_xXActive fungal infection at time of HCTXx_NEWLINE_xXActive fungal, bacterial, and/or viral infection.Xx_NEWLINE_xXHave active, bacterial, viral, or fungal infections, requiring systemic therapyXx_NEWLINE_xXOther serious uncontrolled conditions such as fungal, bacterial or viral infection; HIV, Hepatitis B or C, bleeding disorders, interstitial lung disease,Xx_NEWLINE_xXPatients with active or uncontrolled bacterial, viral, or fungal infections requiring systemic therapyXx_NEWLINE_xXClinically significant active viral, bacterial or fungal infection requiring:Xx_NEWLINE_xXUncontrolled bacterial, fungal or viral infections including human immunodeficiency virus (HIV)-1/2 or active hepatitis C/B - chronic asymptomatic viral hepatitis is allowedXx_NEWLINE_xXPatients with uncontrolled bacterial, viral or fungal infections including diagnosis of acute viral hepatitis (defined as any active infection with hepatitis A or a new diagnosis of hepatitis B or C within 24 weeks of transplant)Xx_NEWLINE_xXPatients with known NCI CTCAE Grade 3 or higher (requiring IV antibiotics) active systemic or cutaneous viral, bacterial, or fungal infection.Xx_NEWLINE_xXEvidence of ongoing systemic bacterial, fungal, or viral infection at the time of enrollmentXx_NEWLINE_xXActive, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.Xx_NEWLINE_xXMust not have an active symptomatic fungal, bacterial or viral infection, including human immunodeficiency virus (HIV) or Hepatitis A, B, or CXx_NEWLINE_xXActive systemic viral, bacterial or fungal infections requiring treatment.Xx_NEWLINE_xXActive systemic fungal, bacterial, and/or viral infection.Xx_NEWLINE_xXActive symptomatic fungal, bacterial and/or viral infection including active HIV or viral hepatitis.Xx_NEWLINE_xXAny active viral, bacterial, or systemic fungal infection within 4 weeks prior study entryXx_NEWLINE_xXOngoing systemic bacterial, fungal, or viral infections at the time of initiation of study treatment (defined as requiring IV antimicrobial, antifungal or antiviral agents) ( Subjects on antimicrobial, antifungal or antiviral prophylaxis are not specifically excluded if all other inclusion/exclusion criteria are met and there is no evidence of active infection at Screening and/or Cycle 1 Day 1 (predose))Xx_NEWLINE_xX216 Presence of fungal, bacterial, viral, or other infection requiring IV antimicrobials for management within 7 days of first dose AMG 562. NOTE: Simple UTI and uncomplicated bacterial pharyngitis are permitted after consultation with sponsor and if responding to active treatment.Xx_NEWLINE_xXActive, uncontrolled urogenital bacterial, viral or fungal infections, including urinary tract infection (UTI). Skin/nail fungal infections are not exclusionary. Subjects with active shingles (varicella zoster infection) will be excluded from the study.Xx_NEWLINE_xXUncontrolled systemic fungal, bacterial, viral or other infection despite appropriate antibiotics or other treatment at the time of leukapheresis or lisocabtagene maraleucel administrationXx_NEWLINE_xXAcute viral, bacterial, or fungal infection, which requires specific therapy. Acute therapy must have been completed at least 7 days prior to study treatment.Xx_NEWLINE_xXActive systemic fungal, bacterial, viral, or other infection, unless disease is under treatment with anti-microbials, and/or controlled or stable (e.g. if specific, effective therapy is not available/feasible or desired [e.g. known chronic viral hepatitis, human immunodeficiency virus (HIV)]); patient needs to be clinically stable as defined as being afebrile and hemodynamically stable for 24 hours; patients with fever thought to be likely secondary to leukemia are eligibleXx_NEWLINE_xXUncontrolled active systemic fungal, bacterial, viral, or other infection or requirement for intravenous (IV) antibioticsXx_NEWLINE_xXPresence of fungal, bacterial, viral, or other infection requiring IV antimicrobials for management\r\n* Note: Simple urinary tract infection (UTI) and uncomplicated bacterial pharyngitis are permitted if responding to active treatmentXx_NEWLINE_xXPatients with uncontrolled bacterial, viral or fungal infections (currently taking medication and progression of clinical symptoms).Xx_NEWLINE_xXUncontrolled viral or bacterial infection at the time of study enrollmentXx_NEWLINE_xXUncontrolled bacterial, fungal or viral infections including HIV-1/2 or active hepatitis C/B - chronic asymptomatic viral hepatitis is allowedXx_NEWLINE_xXUncontrolled systemic fungal, bacterial, viral, or other infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)Xx_NEWLINE_xXSystemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)Xx_NEWLINE_xXHave an active, uncontrolled, systemic fungal, bacterial, or viral infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment.Xx_NEWLINE_xXParticipant had a serious infection within 2 weeks prior to randomization, including any Grade 3 or higher viral, bacterial, or fungal infection.Xx_NEWLINE_xXClinically significant active viral, bacterial or fungal infectionXx_NEWLINE_xXActive, uncontrolled bacterial, viral, or fungal infection requiring systemic therapyXx_NEWLINE_xXEvidence of active viral, bacterial, or systemic fungal infection.Xx_NEWLINE_xXKnown active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at screening or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to cycle 1, day 1Xx_NEWLINE_xXUncontrolled bacterial, viral or fungal infection defined as currently taking antimicrobial therapy and progression of clinical symptomsXx_NEWLINE_xXPatients with a systemic fungal, bacterial, viral, or other infection not controlledXx_NEWLINE_xXActive bacterial or fungal infection; all prior infections must be resolved following optimal therapyXx_NEWLINE_xXActive bacterial, viral, or fungal infectionXx_NEWLINE_xXSerious concomitant disorder, including active bacterial, fungal, or viral infection, incompatible with the study (at the discretion of the principal investigator)Xx_NEWLINE_xXNo current uncontrolled bacterial, viral or fungal infection (defined as currently taking medication and progression of clinical symptoms)Xx_NEWLINE_xXUncontrolled bacterial, viral, or fungal infection (currently taking medication and with progression or no clinical improvement)Xx_NEWLINE_xXCurrent unresolved infection or history of chronic, active, clinically significant infection (viral, bacterial, fungal, or other) which, in the opinion of the Investigator, would preclude the patient from exposure to a biologic agent or pose a risk to patient safetyXx_NEWLINE_xXAny active grade 3 or higher (per NCI CTCAE version 4.03) viral, bacterial, or fungal infection within 2 weeks of the first dose of the study drug. Routine antimicrobial prophylaxis is permitted.Xx_NEWLINE_xXSubject has an uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment).Xx_NEWLINE_xXHas an invasive fungal infection.Xx_NEWLINE_xXactive bacterial, fungal infection, or detectable viral infectionXx_NEWLINE_xXAs judged by the Investigator, any evidence of severe or uncontrolled systemic disease (eg, severe hepatic impairment, interstitial lung disease [bilateral, diffuse, parenchymal lung disease]), or current unstable or uncompensated respiratory or cardiac conditions, or uncontrolled hypertension, history of, or active, bleeding diatheses (eg, hemophilia or von Willebrand disease) or uncontrolled active systemic fungal, bacterial, viral, or other infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment), or intravenous anti-infective treatment within 2 weeks before first dose of study drug.Xx_NEWLINE_xXUncontrolled acute life threatening bacterial, viral or fungal infection (e.g. blood culture positive ? 72 hours prior to infusion)Xx_NEWLINE_xXSubject has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.Xx_NEWLINE_xXActive, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.Xx_NEWLINE_xXAs judged by the Investigator, any evidence of severe or uncontrolled systemic disease (eg, severe hepatic impairment, interstitial lung disease [bilateral, diffuse, parenchymal lung disease]), or current unstable or uncompensated respiratory or cardiac conditions, or uncontrolled hypertension, history of, or active, bleeding diatheses (eg, hemophilia or von Willebrand disease) or uncontrolled active systemic fungal, bacterial, viral, or other infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment), or intravenous anti-infective treatment within 2 weeks before first dose of study drug.Xx_NEWLINE_xXActive viral, bacterial, or systemic fungal infection requiring parenteral treatment within four weeks of enrollment. Patients requiring any oral antiviral, fungal, or bacterial therapy must have completed treatment within one week of enrollment.Xx_NEWLINE_xXUncontrolled acute life threatening bacterial, viral or fungal infectionXx_NEWLINE_xXKnown active infections (bacterial, fungal, viral including HIV positivity).Xx_NEWLINE_xXEvidence of ongoing systemic bacterial, fungal, or viral infection at the time of start of study drugXx_NEWLINE_xXUncontrolled systemic fungal, bacterial, or viral infectionXx_NEWLINE_xXUncontrolled intercurrent illness including, but not limited to, ongoing or active systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics or other treatment), uncontrolled hypertension, cardiac arrhythmia, pneumonitis, interstitial lung disease, active peptic ulcer disease or gastritis that would limit compliance with study requirement.Xx_NEWLINE_xXActive bacterial, viral, or fungal infection requiring systemic treatment at the time of study entry.Xx_NEWLINE_xXHave active bacterial, fungal, and/or known viral infection.Xx_NEWLINE_xXCurrent or recent history (< 21 days prior to start of treatment) of a clinically significant bacterial, viral, fungal, parasitic or mycobacterial infectionXx_NEWLINE_xXPatients must not have a systemic fungal, bacterial, viral or other infection that is not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)Xx_NEWLINE_xXActive bacterial infectionXx_NEWLINE_xXAcute bacterial or fungal infection requiring intravenous antibiotics at the time of registrationXx_NEWLINE_xXActive bacterial, viral, fungal, or other infectionXx_NEWLINE_xXActive uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment)Xx_NEWLINE_xXUncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment)Xx_NEWLINE_xXAcute bacterial or fungal infection requiring intravenous antibiotics at the time of registrationXx_NEWLINE_xXPatients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)Xx_NEWLINE_xXPatients with active bacterial or fungal infections unresponsive to medical therapyXx_NEWLINE_xXSerious systemic fungal, bacterial, viral, or other infection that is not controlled or requires intravenous antibioticsXx_NEWLINE_xXUncontrolled active systemic fungal, bacterial, viral, or other infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment), or intravenous anti-infective treatment within 2 weeks before first dose of study drugXx_NEWLINE_xXKnown active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment or any major episode of infection requiring treatment with intravenous antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to Cycle 1, Day 1Xx_NEWLINE_xXProgressive or persistent viral or bacterial infectionXx_NEWLINE_xXAcute bacterial or fungal infection requiring intravenous antibiotics at the time of registrationXx_NEWLINE_xXActive bacterial infectionXx_NEWLINE_xXKnown active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to Cycle 1 Day 1Xx_NEWLINE_xXActive systemic fungal, bacterial, viral, or other infection, unless disease is under treatment with anti-microbials and/or controlled or stable (e.g. if specific, effective therapy is not available/feasible or desired [e.g. chronic viral hepatitis, human immunodeficiency virus (HIV)]); patient needs to be clinically stable as defined as being afebrile and hemodynamically stable for 24 hours; patients with fever thought to be likely secondary to leukemia are eligibleXx_NEWLINE_xXEvidence of active infection that requires anti-bacterial, anti-viral, or anti-fungal therapy =< 7 days prior to initiation of study drug therapyXx_NEWLINE_xXSystemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)Xx_NEWLINE_xXPatients with a history of active systemic fungal infection.Xx_NEWLINE_xXPatients with uncontrolled bacterial, viral or fungal infections (currently taking medication and progression of clinical symptoms)Xx_NEWLINE_xXCurrent uncontrolled bacterial, viral or fungal infection (currently taking medication with evidence of progression of clinical symptoms or radiologic findings)Xx_NEWLINE_xXPresence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management.Xx_NEWLINE_xXActive viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days of first study drug administrationXx_NEWLINE_xXActive, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapyXx_NEWLINE_xXActive current infection or history of recurrent bacterial, viral, fungal, mycobacterial or other infections, including but not limited to tuberculosis and atypical mycobacterial disease, hepatitis B and C, herpes zoster, and HIV, but excluding fungal infections of nail bedsXx_NEWLINE_xXHave active bacterial or fungal infection (that is, requiring intravenous antibiotics at the time of initiating study treatment) and/or detectable viral infection.Xx_NEWLINE_xXPresence of known active bacterial, fungal, or viral infection requiring systemic therapyXx_NEWLINE_xXKnown active bacterial, viral, fungal, mycobacterial, or other infection (excluding fungal infections of nail beds) or any major episode of infection requiring treatment with IV antibiotics or hospitalization (related to the completion of the course of antibiotics) within 4 weeks before the start of cycle 1Xx_NEWLINE_xXPatients with uncontrolled active infection (viral, bacterial, and fungal) are not eligibleXx_NEWLINE_xXHas any clinically significant infection, i.e., any acute viral, bacterial, or fungal infection that requires specific treatment (anti-infective treatment has to be completed ? 7 days prior to study entry).Xx_NEWLINE_xXThe participant has a known active fungal, bacterial, or viral infection including human immunodeficiency virus (HIV) or viral (A, B, or C) hepatitis (screening is not required).Xx_NEWLINE_xXActive, uncontrolled bacterial, viral, or fungal infections.Xx_NEWLINE_xXAny clinically significant infection defined as any acute viral, bacterial, or fungal infection that requires specific treatment. NOTE: Anti-infective treatment must be completed ? 7 days prior to study registration.Xx_NEWLINE_xXParticipants with active bacterial, viral, or fungal infection requiring systemic treatmentXx_NEWLINE_xXParticipant exhibits evidence of other clinically significant uncontrolled condition(s) including, but not limited to: uncontrolled systemic infection requiring IV therapy (viral, bacterial or fungal).Xx_NEWLINE_xXAny history of current or within the past 48 hours of acute or chronic bacterial, fungal or viral infectious diseaseXx_NEWLINE_xXParticipants with active bacterial, viral, or fungal infection requiring systemic treatment within the last two months prior to registrationXx_NEWLINE_xXActive symptomatic fungal, bacterial and/or viral infection including evidence of infection with human immunodeficiency virus (HIV)Xx_NEWLINE_xXHave active bacterial or fungal infection, or detectable viral infectionXx_NEWLINE_xXHave an active infection of any kind (fungal, viral, or bacterial)Xx_NEWLINE_xXOther clinically significant uncontrolled condition(s) including, but not limited to, systemic infection (viral, bacterial or fungal)Xx_NEWLINE_xXOngoing systemic bacterial, fungal, or viral infections at the time of initiation of study treatment (defined as requiring IV antimicrobial, antifungal or antiviral agents) ? Subjects on antimicrobial, antifungal or antiviral prophylaxis are not specifically excluded if all other inclusion/exclusion criteria are met and there is no evidence of active infection at randomizationXx_NEWLINE_xXActive and clinically significant bacterial, fungal, or viral infectionXx_NEWLINE_xXSystemic fungal, bacterial, viral, or other infection that is not controlledXx_NEWLINE_xXKnown active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to cycle 1, day 1Xx_NEWLINE_xXActive bacterial or systemic viral or fungal infections.Xx_NEWLINE_xXOngoing systemic bacterial, fungal, or viral infections at the time of initiation of study treatment.Xx_NEWLINE_xXUncontrolled bacterial, viral or fungal infectionXx_NEWLINE_xXActive, uncontrolled bacterial, viral or fungal infection requiring systemic therapy.Xx_NEWLINE_xXPatient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.Xx_NEWLINE_xXExhibits evidence of other clinically significant uncontrolled condition(s), including, but not limited to: uncontrolled systemic infection (viral, bacterial, or fungal), diagnosis of fever and neutropenia within 1 week prior to first dose of study drugXx_NEWLINE_xXActive viral, bacterial or fungal infectionXx_NEWLINE_xXUncontrolled bacterial, viral or fungal infections (i.e., currently taking medications with progression of clinical symptoms or signs)Xx_NEWLINE_xXPatients with a systemic fungal, bacterial, viral, or other infection not controlled despite appropriate antibiotics or other treatment; uncontrolled systemic infections require infectious disease consultation for verificationXx_NEWLINE_xXUncontrolled viral or bacterial infection at the time of study enrollmentXx_NEWLINE_xXAny active systemic infection (viral, fungal, or bacterial) requiring active parenteral antibiotic therapy within 4 weeks of study drug administration.Xx_NEWLINE_xXUncontrolled viral, bacteria or fungal infection at time of study enrollmentXx_NEWLINE_xXSubjects with acute infection: any acute viral, bacterial, or fungal infection which requires specific therapy; acute therapy must have been completed more than 14 days prior to study treatmentXx_NEWLINE_xXActive viral, bacterial or fungal infectionXx_NEWLINE_xXSerious non-malignant disease (e.g., active uncontrolled bacterial, viral, or fungal infections) or other medical conditions (including psychiatric) which, in the opinion of the Principal Investigator (PI) would compromise other protocol objectivesXx_NEWLINE_xXUncontrolled systemic fungal, bacterial, viral, or other infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)Xx_NEWLINE_xXActive bacterial, viral or fungal infectionsXx_NEWLINE_xXAny active systemic viral, bacterial, or fungal infection requiring IV treatment with antimicrobial therapy within 1 week prior to first doseXx_NEWLINE_xXSystemic fungal, bacterial, viral, or other infection if not controlled; defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment (may be enrolled if controlled on treatment)Xx_NEWLINE_xXActive bacterial or viral infectionXx_NEWLINE_xXUncontrolled bacterial, viral or fungal infection (currently taking medication and with progression or no clinical improvement).Xx_NEWLINE_xXUncontrolled bacterial or viral infections - chronic asymptomatic viral hepatitis is allowedXx_NEWLINE_xXUncontrolled bacterial, fungal or viral infections including human immunodeficiency virus (HIV) - chronic asymptomatic viral hepatitis is allowedXx_NEWLINE_xXNo uncontrolled bacterial, fungal or viral disease (therapy for cytomegalovirus [CMV] viremia is permitted)Xx_NEWLINE_xXActive bacterial or fungal infections unresponsive to medical therapyXx_NEWLINE_xXActive fungal, bacterial, and/or viral infectionXx_NEWLINE_xXActive viral, bacterial or fungal infectionXx_NEWLINE_xXUncontrolled systemic bacterial, fungal or viral infectionXx_NEWLINE_xXThe participant has active bacterial infection, fungal infection, or detectable viral infection or viral load.Xx_NEWLINE_xXActive bacterial, fungal or viral infections requiring treatment with intravenous (IV) antibiotic, IV antifungal, or IV anti-viral drugsXx_NEWLINE_xXInvasive fungal or viral infection not responding to appropriate antifungal or antiviral therapies.Xx_NEWLINE_xXKnown active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) or any major episode of infection requiring treatment with intravenous antibiotics or hospitalization within 4 weeksXx_NEWLINE_xXSystemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)Xx_NEWLINE_xXPatients with other conditions not related to leukemic relapse (e.g. veno-occlusive disease or uncontrolled bacterial, viral or invasive fungal infection) which are also life-threatening and which would preclude evaluation of the effects of a T cell infusionXx_NEWLINE_xXActive bacterial or fungal infections unresponsive to medical therapyXx_NEWLINE_xXPatients will be excluded if they have a systemic fungal, bacterial, viral or other infection of which they exhibit ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics or other treatment; the patient needs to be off all pressor medications and have negative blood cultures for at least 48 hoursXx_NEWLINE_xXCurrently known uncontrolled bacterial, viral, fungal, HIV, hepatitis B, or hepatitis C infectionXx_NEWLINE_xXEvidence of ongoing systemic bacterial, fungal, or viral infection at the time of enrollmentXx_NEWLINE_xXUncontrolled active systemic fungal, bacterial, viral, or other infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)Xx_NEWLINE_xXActive infections (bacterial, fungal, or viral)Xx_NEWLINE_xXOngoing systemic bacterial, fungal or viral infection (with the exception of fungal infections of the skin or nails).Xx_NEWLINE_xXSystemic fungal, bacterial, viral, or other infection that is not controlled, at the time of screeningXx_NEWLINE_xXEvidence of ongoing systemic bacterial, fungal, or viral infection at the time of randomizationXx_NEWLINE_xXPatients will be excluded if they have a systemic fungal, bacterial, viral or other infection that is exhibiting ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics or other treatment.Xx_NEWLINE_xXFungal or viral infection requiring additional therapyXx_NEWLINE_xXEvidence of ongoing systemic bacterial, fungal, or viral infection at the time of enrollmentXx_NEWLINE_xXHave an active, known fungal, bacterial, and/or known viral infection.Xx_NEWLINE_xXPatient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.Xx_NEWLINE_xXCurrent uncontrolled bacterial, viral or fungal infection.Xx_NEWLINE_xXActive, uncontrolled bacterial, viral, or fungal infection requiring systemic therapy at time of screening.Xx_NEWLINE_xXSubject has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.Xx_NEWLINE_xXSystemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)Xx_NEWLINE_xXHave an active infection of any kind (fungal, viral, or bacterial)Xx_NEWLINE_xXOngoing systemic bacterial, fungal, or viral infections at randomization (defined as requiring IV antimicrobial, antifungal or antiviral agents)Xx_NEWLINE_xXActive and clinically significant bacterial, fungal, or viral infectionXx_NEWLINE_xXActive, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapyXx_NEWLINE_xXEvidence of ongoing systemic bacterial, fungal, or viral infection at the time of enrollmentXx_NEWLINE_xXEvidence of uncontrolled, active infection, requiring systemic anti-bacterial, anti-viral or anti-fungal therapy ? 7 days prior to administration of study medicationXx_NEWLINE_xXActive bacterial, fungal or viral infection.Xx_NEWLINE_xXActive, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapyXx_NEWLINE_xXActive, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy.Xx_NEWLINE_xXPatient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapyXx_NEWLINE_xXPatient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapyXx_NEWLINE_xXKnown active bacterial, viral, fungal, mycobacterial, or other infection (excluding fungal infections of nail beds) or any major episode of infection requiring treatment with IV antibiotics or hospitalization (related to the completion of the course of antibiotics) within 4 weeks prior to study enrollmentXx_NEWLINE_xXHave an active, known fungal, bacterial, and/or known viral infection.Xx_NEWLINE_xXPresence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management. Simple UTI and uncomplicated bacterial pharyngitis are permitted if responding to active treatmentXx_NEWLINE_xXActive symptomatic fungal, bacterial and/or viral infection including evidence of infection with HIV, HTL, positive serology for HCV or HBV (acute or chronic infection based on CDC guidelines)Xx_NEWLINE_xXKnown active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (including human immunodeficiency virus [HIV] and atypical mycobacterial disease but excluding fungal infections of the nail beds) at study enrollment or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to Cycle 1, Day 1Xx_NEWLINE_xXHave a known active fungal, bacterial, and/or known viral infection. Hepatocellular cancer participants with chronic viral (B or C) hepatitis are eligible if they retain adequate liver function.Xx_NEWLINE_xXActive uncontrolled bacterial, viral or fungal infections.Xx_NEWLINE_xXViral, bacterial, or fungal infection within 2 weeks prior to the first dose of treatment.Xx_NEWLINE_xXHave an active fungal, bacterial, and/or known viral infection including human immunodeficiency virus (HIV) or viral (A, B, or C) hepatitis (screening is not required).Xx_NEWLINE_xXUncontrolled bacterial, viral, or fungal infectionsXx_NEWLINE_xXPatients will be excluded if they have a systemic fungal, bacterial, viral or other infection that is exhibiting ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics or other treatment.Xx_NEWLINE_xXPatients with uncontrolled active infections (viral, bacterial, and fungal are not eligible)Xx_NEWLINE_xXEvidence of ongoing systemic bacterial, fungal, or viral infection (excluding viral upper respiratory tract infections) at the time of initiation of study treatmentXx_NEWLINE_xXEvidence of uncontrolled systemic bacterial, fungal, or viral infection at the start of study drugXx_NEWLINE_xXActive viral, bacterial or fungal infection requiring intravenous treatment with antimicrobial therapy starting less than four weeks prior to first dose.Xx_NEWLINE_xXSubject has serious/active bacterial, viral or fungal infection requiring systemic treatment.Xx_NEWLINE_xXActive bacterial, viral, or fungal infectionXx_NEWLINE_xXSubject has an active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy, defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment.Xx_NEWLINE_xXDoes not have current uncontrolled bacterial, fungal, or viral infectionXx_NEWLINE_xXMust not have an active symptomatic fungal, bacterial or viral infection, including human immunodeficiency virus (HIV) or Hepatitis A, B, or C.Xx_NEWLINE_xXPatient has a current uncontrolled bacterial, fungal, or viral infection per the judgment of the principal investigator (PI)Xx_NEWLINE_xXKnown active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment or any major episode of infection requiring treatment with intravenous antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to Cycle 1 Day 1Xx_NEWLINE_xXPatients with uncontrolled active infections (viral, bacterial, and fungal) are not eligibleXx_NEWLINE_xXActive and clinically significant bacterial, fungal or viral infectionXx_NEWLINE_xXKnown active fungal, bacterial, and/or known viral infection including human immunodeficiency (HIV) or viral (A, B, or C) hepatitis (screening is not required).;Xx_NEWLINE_xXActive, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.Xx_NEWLINE_xXHistory of other malignancy that could affect compliance with the protocol or interpretation of results Known active bacterial, viral, fungal, mycobacterial, or other infection (excluding fungal infections of nail beds) or any major episode of infection requiring treatment with IV antibiotics or hospitalization (related to the completion of the course of antibiotics) within 4 weeks before the start of Cycle 1Xx_NEWLINE_xXPatients with active fungal, viral, or bacterial infectionsXx_NEWLINE_xXHistory of active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 14 daysXx_NEWLINE_xXActive systemic fungal, bacterial, viral, or other infection, unless under treatment with anti-microbials and controlled/stable, as defined as being afebrile and hemodynamically stable for 24-48 hoursXx_NEWLINE_xXPatients with uncontrolled active infections (viral, bacterial, and fungal are not eligible)Xx_NEWLINE_xXActive systemic fungal, bacterial, viral, or other infection, unless disease is under treatment with anti-microbials and/or controlled or stable (e.g. if specific, effective therapy is not available/feasible or desired [e.g. chronic viral hepatitis, human immunodeficiency virus (HIV)]); patient needs to be clinically stable as defined as being afebrile and hemodynamically stable for 24 hours; patients with fever thought to be likely secondary to leukemia are eligibleXx_NEWLINE_xXActive, uncontrolled bacterial, viral, or fungal infections, including urinary tract infection, within 7 days of study entry requiring systemic therapyXx_NEWLINE_xXActive, uncontrolled bacterial, viral, or fungal infections requiring systemic therapyXx_NEWLINE_xXKnown active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment or any major episode of infection requiring treatment with IV antibiotics or hospitalization within 4 weeks prior to Cycle 1 Day 1Xx_NEWLINE_xXActive uncontrolled bacteria, fungal or viral infectionXx_NEWLINE_xXAcute bacterial or fungal infection requiring intravenous antibiotics at the time of registrationXx_NEWLINE_xXActive, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapyXx_NEWLINE_xXDoes not have current uncontrolled bacterial, fungal, or viral infection per the judgment of the principal investigator (PI)Xx_NEWLINE_xXActive systemic viral, bacterial, or fungal infection requiring antimicrobial, antiviral therapy or antifungal therapy within 2 weeks prior to the first dose of study drug (routine antimicrobial prophylaxis is acceptable)Xx_NEWLINE_xXEvidence of active infection, requiring parenteral anti-bacterial, anti-viral or anti-fungal therapy < 7 days prior to administration of study medicationXx_NEWLINE_xXKnown active bacterial, viral, fungal, mycobacterial, or other infection (including human immunodeficiency virus [HIV] and atypical mycobacterial disease, but excluding fungal infections of the nail beds)Xx_NEWLINE_xXKnown active bacterial, viral, fungal, mycobacterial, or other infection (including HIV and atypical mycobacterial disease, but excluding fungal infections of the nail beds)Xx_NEWLINE_xXHave a known active fungal, bacterial, and/or known viral infection including human immunodeficiency (HIV) or viral (A, B, or C) hepatitis (screening is not required)Xx_NEWLINE_xXSerious nonmalignant disease (e.g., congestive heart failure, hydronephrosis); active uncontrolled bacterial, viral, or fungal infections; or other conditions which would compromise protocol objectives in the opinion of the investigatorXx_NEWLINE_xXAcute bacterial or fungal infection requiring intravenous antibiotics at the time of registrationXx_NEWLINE_xXParticipant with a systemic fungal, bacterial, viral or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement), despite appropriate antibiotics or other treatment)Xx_NEWLINE_xXActive bacterial infectionXx_NEWLINE_xXUncontrolled bacterial, viral or fungal infections (currently taking medication and progression of clinical symptoms)Xx_NEWLINE_xXKnown active bacterial, viral, fungal, mycobacterial, parasitic, or other infectionXx_NEWLINE_xXAny history of recent serious bacterial, viral, fungal, or other opportunistic infections, precluding a stem cell transplant according to the treating physicianXx_NEWLINE_xXPatients with uncontrolled active infection (viral, bacterial, and fungal) are not eligibleXx_NEWLINE_xXPatients with uncontrolled bacteria, viral or fungal infections (currently taking medication and progression of clinical symptoms)Xx_NEWLINE_xXSystemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)Xx_NEWLINE_xXSystemic infection requiring parenteral antibiotic therapy or other serious infection (bacterial, fungal, or viral) within 21 days before the first dose of study drug.Xx_NEWLINE_xXActive uncontrolled bacterial or invasive fungal infectionsXx_NEWLINE_xXAcute bacterial or fungal infection requiring intravenous antibiotics at the time of registration.Xx_NEWLINE_xXEvidence of any viral, bacterial, or fungal infection involving the lung and not responding to appropriate treatmentXx_NEWLINE_xXActive infection (symptomatic bacterial and fungal infection – newly diagnosed and/or requiring treatment)Xx_NEWLINE_xXPatients with a documented active infection prior to starting their preparative regimen; this includes grade 3 or higher viral, bacterial, or fungal infectionXx_NEWLINE_xXPatients with a documented active infection prior to starting their preparative regimen; this includes grade 3 or higher viral, bacterial, or fungal infectionXx_NEWLINE_xXPatients with a documented active infection prior to starting their preparative regimen; this includes grade 3 or higher viral, bacterial, or fungal infectionXx_NEWLINE_xXPatients with other conditions not related to CMV infection (e.g. uncontrolled bacterial sepsis or invasive fungal infection) which are also life-threatening and which would preclude evaluation of the effects of a T-cell infusionXx_NEWLINE_xXUncontrolled viral, bacterial, fungal or protozoal infection at the time of study enrollmentXx_NEWLINE_xXPatients with active or uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapyXx_NEWLINE_xXActive, uncontrolled urogenital bacterial, viral or fungal infections, including urinary tract infection that in the opinion of the investigator, contraindicates participation. Skin/nail fungal infections are not exclusionary. Subjects with active shingles (varicella zoster infection) will be excluded from the study.Xx_NEWLINE_xXActive acute or chronic systemic fungal, bacterial, or viral infection not well controlled by antifungal, antibacterial or antiviral therapy;Xx_NEWLINE_xXActive viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days of first study drug administrationXx_NEWLINE_xXUncontrolled bacterial, viral or fungal infectionsXx_NEWLINE_xXSpecifically diagnosed and uncontrolled fungal, bacterial, viral, or other infection (e.g. confirmed sepsis, pneumonia, abscess, cellulitis, etc.) at the day chemotherapy is initiated. \Uncontrolled\ is defined as exhibiting ongoing signs and symptoms of infection without improvement despite antimicrobial or other treatment.Xx_NEWLINE_xXUncontrolled bacterial, viral infection or invasive fungal infectionXx_NEWLINE_xXPatients with uncontrolled bacterial, viral or fungal infections (currently taking medication and with progression or no clinical improvement) at time of enrollmentXx_NEWLINE_xXCurrently uncontrolled bacterial, viral, or fungal infection (progression of clinical symptoms despite therapy);Xx_NEWLINE_xXPatients with uncontrolled bacterial, viral or final infections (currently taking medication ad with progression or no clinical improvement) at time of enrollmentXx_NEWLINE_xXActive bacterial, viral, fungal infection not controlled with appropriate antimicrobial therapyXx_NEWLINE_xXNo uncontrolled bacterial, viral or fungal infection at time of enrollment defined as currently taking medication and progression of clinical symptomsXx_NEWLINE_xXSubjects who are being treated for fungal, viral, or bacterial pneumoniaXx_NEWLINE_xXCurrent or previous history of liver, gastrointestinal, hematopoietic, cardiac or renal disease, viral, bacterial, atypical or fungal infections of any organ system and human immunodeficiency virus (HIV) infectionXx_NEWLINE_xXUncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment)Xx_NEWLINE_xXCurrent uncontrolled bacterial, viral or fungal infection (currently taking medication with evidence of progression of clinical symptoms or radiologic findings).Xx_NEWLINE_xXUncontrolled bacterial, viral or fungal infection at the time of leukapheresis, lymphodepleting chemotherapy or JCAR017 infusionXx_NEWLINE_xXPatients with uncontrolled bacterial, viral or fungal infections (currently taking medication and with progression or no clinical improvement) at time of enrollmentXx_NEWLINE_xXPatients with uncontrolled bacterial, viral or fungal infections (currently taking medication and with progression or no clinical improvement) at time of enrollment.Xx_NEWLINE_xXActive, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapyXx_NEWLINE_xXKnown active bacterial, viral, fungal, mycobacterial infection, or other infection (including tuberculosis [TB] or atypical mycobacterial disease [but excluding fungal infection of nail beds, minor upper respiratory tract infection, and minor skin conditions]), or any major episode of infection that required hospitalization or treatment with IV antibiotics within 30 days of study drug administration or oral antibiotics within 14 days prior to study drug administration.Xx_NEWLINE_xXPresence of fungal, bacterial, viral, or other infection requiring IV antimicrobials for management.Xx_NEWLINE_xXActive viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days prior to the initiation of study drug.Xx_NEWLINE_xXSubject has an uncontrolled infection. If a bacterial or viral infection is present, the subject must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to randomization. If a fungal infection is present, the subject must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to randomization.Xx_NEWLINE_xXInvasive bacterial infectionXx_NEWLINE_xXSubjects with active fungal, viral, or bacterial infections.Xx_NEWLINE_xXActive serious systemic disease, including active bacterial or fungal infection within 2 weeks before study entryXx_NEWLINE_xXHave an active fungal, bacterial, and/or known viral infection, including human immunodeficiency virus (HIV) or viral (B or C) hepatitis.Xx_NEWLINE_xXEvidence of any serious bacterial, viral, parasitic or systemic fungal infections within the 30 days prior to study entryXx_NEWLINE_xXUncontrolled systemic fungal, bacterial or viral infection at time of enrollment (defined as ongoing signs/symptoms related the infection without improvement despite appropriate antibiotics, antiviral therapy and/or other treatment).Xx_NEWLINE_xXAcute bacterial or fungal infection requiring intravenous antibiotics at the time of randomizationXx_NEWLINE_xXEvidence of any active, uncontrolled bacterial, viral, parasitic fungal infections within 1 week of first dose of study drugXx_NEWLINE_xX